Chronic hepatitis C virus (HCV) disease burden and cost in the United States H Razavi, AC ElKhoury, E Elbasha, C Estes, K Pasini, T Poynard, ... Hepatology 57 (6), 2164-2170, 2013 | 621 | 2013 |
Model for assessing human papillomavirus vaccination strategies EH Elbasha, EJ Dasbach, RP Insinga Emerging infectious diseases 13 (1), 28, 2007 | 589 | 2007 |
Impact of vaccinating boys and men against HPV in the United States EH Elbasha, EJ Dasbach Vaccine 28 (42), 6858-6867, 2010 | 283 | 2010 |
Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV … RP Insinga, EJ Dasbach, EH Elbasha BMC infectious diseases 9, 1-26, 2009 | 278 | 2009 |
Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature RP Insinga, EJ Dasbach, EH Elbasha Pharmacoeconomics 23, 1107-1122, 2005 | 251 | 2005 |
Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease EJ Dasbach, EH Elbasha, RP Insinga Epidemiologic reviews 28 (1), 88-100, 2006 | 220 | 2006 |
Role of incidence function in vaccine-induced backward bifurcation in some HIV models O Sharomi, CN Podder, AB Gumel, EH Elbasha, J Watmough Mathematical Biosciences 210 (2), 436-463, 2007 | 199 | 2007 |
A primer on using mathematics to understand COVID-19 dynamics: Modeling, analysis and simulations AB Gumel, EA Iboi, CN Ngonghala, EH Elbasha Infectious Disease Modelling 6, 148-168, 2021 | 169 | 2021 |
On endogenous growth: the implications of environmental externalities EH Elbasha, TL Roe Journal of Environmental Economics and Management 31 (2), 240-268, 1996 | 169 | 1996 |
Theoretical assessment of public health impact of imperfect prophylactic HIV-1 vaccines with therapeutic benefits EH Elbasha, AB Gumel Bulletin of mathematical biology 68, 577-614, 2006 | 142 | 2006 |
Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance RP Insinga, G Perez, CM Wheeler, LA Koutsky, SM Garland, S Leodolter, ... Cancer Epidemiology, Biomarkers & Prevention 20 (2), 287-296, 2011 | 137 | 2011 |
Vaccination against multiple HPV types EH Elbasha, AP Galvani Mathematical biosciences 197 (1), 88-117, 2005 | 136 | 2005 |
Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives RP Insinga, EJ Dasbach, EH Elbasha, KL Liaw, E Barr Cancer Epidemiology Biomarkers & Prevention 16 (4), 709-715, 2007 | 126 | 2007 |
Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation RP Insinga, EJ Dasbach, EH Elbasha, A Puig, LM Reynales-Shigematsu Vaccine 26 (1), 128-139, 2007 | 123 | 2007 |
Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women RP Insinga, G Perez, CM Wheeler, LA Koutsky, SM Garland, S Leodolter, ... Cancer epidemiology, biomarkers & prevention 19 (6), 1585-1594, 2010 | 109 | 2010 |
The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK EJ Dasbach, RP Insinga, EH Elbasha BJOG: An International Journal of Obstetrics & Gynaecology 115 (8), 947-956, 2008 | 102 | 2008 |
An ex post economic impact assessment of planted forages in West Africa E Elbasha, PK Thornton, G Tarawali ILRI (aka ILCA and ILRAD), 1999 | 98* | 1999 |
Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women RP Insinga, EJ Dasbach, EH Elbasha, KL Liaw, E Barr Infectious agents and cancer 2, 1-10, 2007 | 89 | 2007 |
Deadweight loss of bacterial resistance due to overtreatment EH Elbasha Health economics 12 (2), 125-138, 2003 | 83 | 2003 |
A multi-type HPV transmission model EH Elbasha, EJ Dasbach, RP Insinga Bulletin of mathematical biology 70, 2126-2176, 2008 | 82 | 2008 |